The tablets, used to treat a potassium deficiency, are a generic version of K Dur tablets produced by Merck Sharp & Dohm, a subsidiary of Kenilworth, N.J.-based Merck.
The K Dur tablets reported annual sales of $283 million for the 12-month period ending May 2016, according to IMS Health sales data.
India-based Glenmark Pharmaceuticals currently has 117 products authorized for distribution in the U.S. and 61 products pending approval from the FDA.
More articles on the drug market:
Patients in Texas and Florida gain easier access to opioid-overdose antidote naloxone
Eli Lily exceeds 2Q expectations thanks to new drug sales
Sen. Bernie Sanders’ DNC speech tackles high prescription drug costs: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
